News

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.

Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction cancers.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued.

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.

In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with Ewing sarcoma.

Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.

In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

In an interview, Craig A. Portell, MD, offered an in-depth look at sequencing therapies in relapsed/refractory mantle cell lymphoma.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic leukemia with comorbidities.

ALLO-316 demonstrated a 50% overall response rate and 33% complete response rate in CD70-positive advanced RCC in the phase 1 TRAVERSE trial.

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing apalutamide with abiraterone acetate.

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung cancer, with a safety profile similar to earlier studies.

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be discussed at the upcoming 19th Annual New York Lung Cancers Symposium®.

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

In an interview with Targeted Oncology, Ariel Lopez-Chavez, MD, discussed recent developments in the small cell lung cancer space.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Craig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma treatment.